The efficacy beat vs Otezla seems substantial. Nothing about safety in this PR raises alarms to me. This could be a big drug for BMY. It could be a really big drug if it also works well in other autoimmune conditions, although the space is obviously competitive
EDIT: I see you beat me to it and posted the slides..
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.